Repurposing of Ribavirin as an Adjunct Therapy against Invasive Candida Strains in an In Vitro Study

The use of antifungal agents in clinical settings is limited by the appearance of drug resistance and adverse side effects. There is, therefore, an urgent need to develop new drugs to strengthen the treatment of invasive fungal diseases. The aim of this study is to describe the potential repurposing of ribavirin as an adjunct therapy against Candida spp. Primary screening of a Prestwick Chemical library against Candida albicans ATCC 90028 and fluconazole-resistant Candida albicans strains was performed. ABSTRACT The use of antifungal agents in clinical settings is limited by the appearance of drug resistance and adverse side effects. There is, therefore, an urgent need to develop new drugs to strengthen the treatment of invasive fungal diseases. The aim of this study is to describe the potential repurposing of ribavirin as an adjunct therapy against Candida spp. Primary screening of a Prestwick Chemical library against Candida albicans ATCC 90028 and fluconazole-resistant Candida albicans strains was performed. Subsequently, we evaluated the responses of 100 Candida sp. strains to ribavirin, an antiviral agent, using the broth microdilution method as recommended by CLSI. We checked the involvement of efflux pump activity in the development of ribavirin resistance. We studied time-kill curves and performed a checkerboard assay for a ribavirin-antifungal combination study. Twenty-one nonstandard antifungal compounds were identified, including ribavirin. Ribavirin had antifungal activity in vitro against 63 Candida strains, including strains of C. albicans, C. parapsilosis, and C. tropicalis, with MICs ranging from 0.37 to 3.02 μg/ml, while MICs for C. krusei, C. glabrata, C. lusitaniae, and some C. albicans strains remained high (≥24.16 μg/ml). No relation was observed between efflux pump activity and ribavirin resistance. Ribavirin exhibited fungistatic activity against multidrug-resistant (MDR) C. albicans and fungicidal activity against a C. parapsilosis strain. In addition, ribavirin acted synergistically with azoles against Candida strains for which ribavirin MICs were <24.4 μg/ml. This study highlights the potential clinical application of ribavirin, alone or in association with other antifungal agents, as an adjunct anti-Candida drug.

[1]  J. Geddes-McAlister,et al.  New pathogens, new tricks: emerging, drug‐resistant fungal pathogens and future prospects for antifungal therapeutics , 2019, Annals of the New York Academy of Sciences.

[2]  R. Ratnaparkhi,et al.  Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients , 2018, Pediatric dermatology.

[3]  Leigh G. Monahan,et al.  Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis , 2018, PeerJ.

[4]  J. Rolain,et al.  Zidovudine: A salvage therapy for mcr-1 plasmid-mediated colistin-resistant bacterial infections? , 2018, International journal of antimicrobial agents.

[5]  K. Hanson,et al.  Candida auris: an Emerging Fungal Pathogen , 2017, Journal of Clinical Microbiology.

[6]  Anand K. Ramasubramanian,et al.  Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi , 2017, Virulence.

[7]  J. Cardelli,et al.  Identification of small molecules that disrupt vacuolar function in the pathogen Candida albicans , 2017, PloS one.

[8]  J. Timsit,et al.  The current treatment landscape: candidiasis. , 2016, The Journal of antimicrobial chemotherapy.

[9]  S. Ranque,et al.  Performance of MALDI‐TOF MS platforms for fungal identification , 2016, Mycoses.

[10]  Jeffrey B Locke,et al.  Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species , 2016, Antimicrobial Agents and Chemotherapy.

[11]  A. O. Ogundeji,et al.  Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs , 2016, Antimicrobial Agents and Chemotherapy.

[12]  S. Gerber,et al.  Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review , 2015, Archives of Gynecology and Obstetrics.

[13]  S. Brunke,et al.  Antifungal activity of clotrimazole against Candida albicans depends on carbon sources, growth phase and morphology. , 2015, Journal of medical microbiology.

[14]  Kevin Kim,et al.  Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans , 2015, Annals of Clinical Microbiology and Antimicrobials.

[15]  James H. Jorgensen,et al.  Manual of Clinical Microbiology, 11th Edition , 2015 .

[16]  Mickael Guedj,et al.  Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.

[17]  P. Cos,et al.  Artemisinins, New Miconazole Potentiators Resulting in Increased Activity against Candida albicans Biofilms , 2014, Antimicrobial Agents and Chemotherapy.

[18]  Rajendra Prasad,et al.  Efflux pump proteins in antifungal resistance , 2014, Front. Pharmacol..

[19]  I. Olsen.  Attenuation of Candida albicans virulence with focus on disruption of its vacuole functions , 2014, Journal of oral microbiology.

[20]  T. Liang,et al.  The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C , 2012, Antiviral chemistry & chemotherapy.

[21]  A. Gácser,et al.  Candida parapsilosis, an Emerging Fungal Pathogen , 2008, Clinical Microbiology Reviews.

[22]  A. Rattan,et al.  Antifungal potential of disulfiram. , 2007, Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology.

[23]  G. Randall,et al.  Mechanism of action of ribavirin in the treatment of chronic hepatitis C. , 2007, Gastroenterology & hepatology.

[24]  C. Eken,et al.  Abamectin intoxication with coma and hypotension , 2007, Clinical toxicology.

[25]  T. Peláez,et al.  Fluconazole resistance mechanisms in Candida krusei: the contribution of efflux-pumps. , 2006, Medical mycology.

[26]  A. Bruchfeld,et al.  High‐dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C , 2005, Hepatology.

[27]  M. Schaller,et al.  Ciclopirox Olamine Treatment Affects the Expression Pattern of Candida albicans Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors , 2003, Antimicrobial Agents and Chemotherapy.

[28]  G. Hajian,et al.  Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C , 2000, Therapeutic drug monitoring.

[29]  M. Leibowitz,et al.  Pentamidine Inhibition of Group I Intron Splicing in Candida albicans Correlates with Growth Inhibition , 2000, Antimicrobial Agents and Chemotherapy.

[30]  G. Davis,et al.  Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial , 1997, Hepatology.

[31]  Ronald N. Jones,et al.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans , 1997, Antimicrobial agents and chemotherapy.

[32]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .

[33]  M. Pfaller,et al.  Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. , 2012, The American journal of medicine.

[34]  A. Azcurra,et al.  Antifungal and post-antifungal effects of chlorhexidine, fluconazole, chitosan and its combinations on Candida albicans. , 2011, Medicina oral, patologia oral y cirugia bucal.

[35]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .